Termination of Material Agreement (Form 8-K)

Item 1.02. Termination of a Material Definitive Agreement.

On July 23, 2026, OS Therapies Incorporated (the "Company") delivered to B. Riley Securities, Inc. and JonesTrading Institutional Services LLC (together, the "Sales Agents") written notice of termination of the At Market Issuance Sales Agreement, dated August 8, 2025 (the "Sales Agreement"), between the Company and the Sales Agents, pursuant to Sections 13(b) and 14 thereof. The termination became effective on July 28, 2026.

As previously disclosed, the Sales Agreement provided the Company with the ability to offer and sell shares of its common stock from time to time having an aggregate offering price of up to $18,000,000 through or to the Sales Agents. On August 25, 2025, the Company filed a prospectus supplement relating to the Sales Agreement (the "Prospectus Supplement"), pursuant to which the Company could offer and sell shares of its common stock having an aggregate offering price of up to $18,000,000. At the time the Company delivered the notice to terminate, and at the time of termination, the Company had sold an aggregate of 282,679 shares of its common stock for aggregate gross proceeds of approximately $530,162 under the Sales Agreement and the Prospectus Supplement, and approximately $17,469,838 remained unsold thereunder. No further shares of the Company's common stock may or will be offered or sold under the Sales Agreement or the Prospectus Supplement. In addition, no termination fees or other payments were due by either party in connection with the termination of the Sales Agreement.